AR019953A1 - Formas cristalinas i y ii de (r)-(+)-n-[[3-[1-benzoil-3-(3,4-diclorofenil)piperidin-3-il]prop-1-il]-4-fenilpiperidin-4-il]-n-metilacetamida (osanetant),composicion farmaeutica que las comprende y procedimiento para su preparacion de acuerdo a la mezcla de solvente y temperatura utilizado - Google Patents
Formas cristalinas i y ii de (r)-(+)-n-[[3-[1-benzoil-3-(3,4-diclorofenil)piperidin-3-il]prop-1-il]-4-fenilpiperidin-4-il]-n-metilacetamida (osanetant),composicion farmaeutica que las comprende y procedimiento para su preparacion de acuerdo a la mezcla de solvente y temperatura utilizadoInfo
- Publication number
- AR019953A1 AR019953A1 ARP990103741A ARP990103741A AR019953A1 AR 019953 A1 AR019953 A1 AR 019953A1 AR P990103741 A ARP990103741 A AR P990103741A AR P990103741 A ARP990103741 A AR P990103741A AR 019953 A1 AR019953 A1 AR 019953A1
- Authority
- AR
- Argentina
- Prior art keywords
- osanetant
- piperidin
- methylacetamide
- pharmaceutical composition
- diclorophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a un procedimiento para la preparacion de las formas cristalinas I y II de (R)-(+)-N-[[3-[1-benzoil-3-(3,4-diclorofenil)piperidin-3-il]-4-fenil-piperidin-4-il]-N-metilacetamida (osanetant), i) el osanetant es cristalizado a partir de unam ezcla de etanol/agua o de isopropanol para proporcionar la formaI; ii) el osanetant es cristalizado a partir de una mezcla de etanol/éter isopropílico/agua para dar la cristalina II, utilizando diferentes mezclas desolventes y temperaturas.También s e describen dichas formas cristalinas I y II de Osanetant y una composicion farmacéuticamente que los comprende.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9810107A FR2782082B3 (fr) | 1998-08-05 | 1998-08-05 | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR019953A1 true AR019953A1 (es) | 2002-03-27 |
Family
ID=9529458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103741A AR019953A1 (es) | 1998-08-05 | 1999-07-28 | Formas cristalinas i y ii de (r)-(+)-n-[[3-[1-benzoil-3-(3,4-diclorofenil)piperidin-3-il]prop-1-il]-4-fenilpiperidin-4-il]-n-metilacetamida (osanetant),composicion farmaeutica que las comprende y procedimiento para su preparacion de acuerdo a la mezcla de solvente y temperatura utilizado |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7041679B2 (es) |
| EP (1) | EP1102747B1 (es) |
| JP (1) | JP3807938B2 (es) |
| KR (1) | KR100571944B1 (es) |
| CN (1) | CN1114592C (es) |
| AR (1) | AR019953A1 (es) |
| AT (1) | ATE243197T1 (es) |
| AU (1) | AU748177B2 (es) |
| BR (1) | BR9913357A (es) |
| CA (1) | CA2339007A1 (es) |
| CO (1) | CO5070576A1 (es) |
| DE (1) | DE69908951T2 (es) |
| DK (1) | DK1102747T3 (es) |
| DZ (1) | DZ3074A1 (es) |
| EA (1) | EA003205B1 (es) |
| EE (1) | EE04274B1 (es) |
| ES (1) | ES2200535T3 (es) |
| FR (1) | FR2782082B3 (es) |
| HK (1) | HK1035535A1 (es) |
| HU (1) | HUP0103134A3 (es) |
| IS (1) | IS5821A (es) |
| MY (1) | MY121447A (es) |
| NO (1) | NO320645B1 (es) |
| NZ (1) | NZ509561A (es) |
| PL (1) | PL345999A1 (es) |
| PT (1) | PT1102747E (es) |
| SK (1) | SK1742001A3 (es) |
| TR (1) | TR200100261T2 (es) |
| TW (1) | TW527354B (es) |
| UA (1) | UA72890C2 (es) |
| WO (1) | WO2000007987A1 (es) |
| YU (1) | YU8601A (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| US7648992B2 (en) * | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| TW200800954A (en) * | 2006-03-16 | 2008-01-01 | Astrazeneca Ab | Novel crystal modifications |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| TW202317533A (zh) * | 2021-07-02 | 2023-05-01 | 美商雅斯治療公司 | 奧沙奈坦(osanetant)之固體形式 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
| JPH1053576A (ja) * | 1996-06-07 | 1998-02-24 | Eisai Co Ltd | 塩酸ドネペジルの多形結晶およびその製造法 |
| JP2000515534A (ja) * | 1996-08-05 | 2000-11-21 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | ３，３―二置換ピペリジンの製造方法 |
| US6040316A (en) * | 1996-09-16 | 2000-03-21 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
-
1998
- 1998-08-05 FR FR9810107A patent/FR2782082B3/fr not_active Expired - Lifetime
-
1999
- 1999-07-25 DZ DZ990156A patent/DZ3074A1/xx active
- 1999-07-28 AR ARP990103741A patent/AR019953A1/es unknown
- 1999-08-03 NZ NZ509561A patent/NZ509561A/xx unknown
- 1999-08-03 AT AT99936672T patent/ATE243197T1/de not_active IP Right Cessation
- 1999-08-03 MY MYPI99003297A patent/MY121447A/en unknown
- 1999-08-03 PL PL99345999A patent/PL345999A1/xx not_active Application Discontinuation
- 1999-08-03 DK DK99936672T patent/DK1102747T3/da active
- 1999-08-03 AU AU51685/99A patent/AU748177B2/en not_active Ceased
- 1999-08-03 SK SK174-2001A patent/SK1742001A3/sk unknown
- 1999-08-03 ES ES99936672T patent/ES2200535T3/es not_active Expired - Lifetime
- 1999-08-03 TR TR2001/00261T patent/TR200100261T2/xx unknown
- 1999-08-03 CA CA002339007A patent/CA2339007A1/en not_active Abandoned
- 1999-08-03 HU HU0103134A patent/HUP0103134A3/hu unknown
- 1999-08-03 CN CN99810182A patent/CN1114592C/zh not_active Expired - Fee Related
- 1999-08-03 KR KR1020017001460A patent/KR100571944B1/ko not_active IP Right Cessation
- 1999-08-03 JP JP2000563621A patent/JP3807938B2/ja not_active Expired - Fee Related
- 1999-08-03 EA EA200100096A patent/EA003205B1/ru not_active IP Right Cessation
- 1999-08-03 YU YU8601A patent/YU8601A/sh unknown
- 1999-08-03 UA UA2001010591A patent/UA72890C2/xx unknown
- 1999-08-03 EE EEP200100070A patent/EE04274B1/xx not_active IP Right Cessation
- 1999-08-03 WO PCT/FR1999/001914 patent/WO2000007987A1/fr not_active Application Discontinuation
- 1999-08-03 EP EP99936672A patent/EP1102747B1/fr not_active Expired - Lifetime
- 1999-08-03 DE DE69908951T patent/DE69908951T2/de not_active Expired - Fee Related
- 1999-08-03 BR BR9913357-1A patent/BR9913357A/pt not_active IP Right Cessation
- 1999-08-03 PT PT99936672T patent/PT1102747E/pt unknown
- 1999-08-04 CO CO99049286A patent/CO5070576A1/es unknown
- 1999-08-04 TW TW088113235A patent/TW527354B/zh not_active IP Right Cessation
-
2001
- 2001-01-23 IS IS5821A patent/IS5821A/is unknown
- 2001-02-01 NO NO20010553A patent/NO320645B1/no unknown
- 2001-09-04 HK HK01106232A patent/HK1035535A1/xx not_active IP Right Cessation
-
2003
- 2003-08-28 US US10/651,313 patent/US7041679B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5011099A1 (es) | Formulaciones en polvo en estado cristalino estable | |
| ES2090713T3 (es) | Sales organicas de n,n'-diacetil-cistina. | |
| AR039666A2 (es) | Procedimiento para la preparacion de la forma i de 6-o-metileritromicina a al vacio, dicho compuesto cristalino aislado asi como sus derivados, el uso de los mismos para la preparacion de un antibiotico, el uso de la forma 0 para prepararla forma i de 6-o-metileritromicina a y otros derivados | |
| CO5271720A1 (es) | Proceso para fabricar selectivamente hemipentahidrato y monopentahidrato de acido 3-piridil-12hidroxi-etiliden-1, 1-bisfofosnico sodio y composicion farmacetica que las contiene | |
| AR019953A1 (es) | Formas cristalinas i y ii de (r)-(+)-n-[[3-[1-benzoil-3-(3,4-diclorofenil)piperidin-3-il]prop-1-il]-4-fenilpiperidin-4-il]-n-metilacetamida (osanetant),composicion farmaeutica que las comprende y procedimiento para su preparacion de acuerdo a la mezcla de solvente y temperatura utilizado | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| ES2158778B1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
| BR0114846A (pt) | Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h | |
| ES2161291T3 (es) | N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa. | |
| KR950032045A (ko) | 비누화된 금잔화 함유수지로부터 얻는 루테인의 분리, 정제 및 재결정방법 | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| BR9714310A (pt) | Composição farmacêutica | |
| SE8404019L (sv) | Oftalmiska antiinflammatoriska medel | |
| NO963370D0 (no) | Nye mercaptoacetylamido-1,3,4,5-tetrahydro-benzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE | |
| DE3887048D1 (de) | Flüssigkristalline, insbesondere ferroelektrische flüssigkristalline Mischungen. | |
| UY27410A1 (es) | Formas novedosas crudas cristalinas | |
| PT96381A (pt) | Processo para a preparacao de derivados de 2-aminopirimidina-4-carboxamida e de composicoes farmaceuticas que os contem | |
| AR008621A1 (es) | Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto | |
| DE3884139T2 (de) | L-Prolin-Derivate, deren Herstellung und deren biologische Anwendungen. | |
| BR9803895A (pt) | Método para produzir um invólucro de estruturas interna, externa e de artigos de equipamento, e método de construção no local usando tal involucro. | |
| CO5011061A1 (es) | Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen | |
| BR0109508A (pt) | Forma ii, cristalina, de cabergolina | |
| AR001259A1 (es) | Proceso para preparar 1,2-bencisotiazolin-3-onas | |
| ES2196783T3 (es) | Nuevo procedimiento de preparacion de la fexofenadina. | |
| ES2182090T3 (es) | Nuevos derivados de pirrol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |